CG

Chris Garabedian

CEO, Xontogeny and Portfolio Manager, PXV Fund

Boston, Massachusetts

Investor
VC

Invests in

Stages:

Series A

  • Min Investment:

    $100,000.00

  • Max Investment:

    $10,000,000.00

  • Target Investment:

    $1,000,000.00

Skills

Biopharmaceuticals
Drug Development
Biotechnology
Product Management
Pharmaceutical Industry
Infectious Diseases
Strategy
Life Sciences
Market Research
Regulatory Affairs
Oncology
Clinical Trials
Product Launch
Strategic Planning
Clinical Development
Product Development
Technology Transfer
Vaccines
Drug Discovery
Marketing Strategy

Education

Lists including Chris

AM
AR
AB
AF

Based in Boston & Cambridge

668 people

AT
AS
AT
AH

All Series A Investors

14752 people

Investments

Marea Therapeutics

Series B

Total Funding: $260M

CereVasc

Series A

Total Funding: $110M

Delve Bio

Series A

Total Funding: $35M

Tellus Therapeutics

Seed

Total Funding: $37M

Peroxitech Therapeutics

Seed

Total Funding: $25M

PolyCore Therapeutics

Seed

Total Funding: $500K

VivoSense

Series A

Total Funding: $25M

Shifa Biomedical

Seed

Total Funding:

Nephraegis Therapeutics

Seed

Total Funding:

Juno Diagnostics

Series A

Total Funding: $25M

Work Experience

X
Xontogeny

2016

  • Chairman and CEO

    2016

PA
Perceptive Advisors

2017

  • Portfolio Manager, Venture (PXV Fund)

    2017

AT
AsclepiX Therapeutics, Inc.

2020

  • Board Member

    2020

C
CereVasc

2020

  • Board Member

    2020

ZT
Zucara Therapeutics Inc.

2020

  • Board Member

    2020

Landos Biopharma, Inc.

2017 - 2024

  • Chairman of the Board

    2017 - 2024

FB
Forge Biologics

2020 - 2023

  • Chairman of the Board

    2020 - 2023

TB
The Boston Consulting Group (BCG)

2016 - 2021

  • Senior Advisor to Healthcare Practice

    2016 - 2021

Quellis Biosciences

2017 - 2021

  • Chairman of the Board

    2017 - 2021

ST
Sarepta Therapeutics

2011 - 2015

  • Chief Executive Officer

    2011 - 2015